A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens

Christine Elser, MD;* Joan Sweet, MD, FRCP;† Sendhil K. Cheran, MD;‡ Masoom A. Haider, MD, FRCPC;§ Michael Jewett, MD, FRCSC;¶ Srikala S. Sridhar, MD, MSc, FRCPC*  

* Medical Oncologist, Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON; †Pathologist, Department of Pathology, University Health Network, Toronto, ON; ‡Radiologist, Department of Radiology, University Health Network, Toronto, ON; ¶Urologist, Department of Urology, Princess Margaret Hospital, Toronto, ON


Abstract

Urachal cancer is a rare form of bladder cancer that arises from the urachus, a vestigial musculofibrous band that extends from the dome of the bladder to the umbilicus. Urachal cancer often presents at an advanced stage and has a dismal prognosis. We present a case of a young woman with urachal cancer that recurred rapidly post-partial cystectomy. The patient was treated with up to 6 different chemotherapy regimens, including an oral antiangiogenic drug as part of a clinical trial. Our case illustrates the aggressive nature of this disease, the difficulty in accessing drugs for the treatment of rare cancers and the lack of late stage clinical trials to help guide therapeutic decisions.

Case report

A 35-year-old woman, who was previously well, presented with an 8-month history of abdominal pain, urinary tract infections and a 4-month history of gross hematuria and bloody discharge from the umbilicus. She underwent a computed tomography (CT) scan which showed a 6.2 × 6.0 × 4.0 cm mass at the dome of the bladder extending anteriorly with trans-serosal involvement and irregular luminal and serosal margins (Fig. 1a). A biopsy of the mass performed via cystoscopy confirmed urachal adenocarcinoma. She then underwent a partial cystectomy to remove the urachus, umbilicus and pelvic lymph nodes. Pathology showed a 6.0 × 5.3 cm mucin producing adenocarcinoma, composed of nests of signet ring cells (Fig. 2a, Fig. 2b). Though the margins were negative, the tumour involved the full thickness of the bladder wall, extended to the perivesical fat and serosal surfaces, showed lymphovascular invasion and involved one of four pelvic lymph nodes. There were also several satellite tumour nodules in the perivesical fat. A restaging magnetic resonance imaging (MRI) performed 6 weeks after the partial cystectomy showed a small enhancing mass in the bladder, but this could not be visualized on cystoscopy. A CT scan 6 weeks later confirmed local recurrence (Fig. 1b) and a total cystectomy was planned. However, at the time of cystectomy, there was extensive peritoneal seeding, and as a result a cystectomy was not performed and the patient was referred to medical oncology for further management.

Five months after her initial diagnosis, repeat staging scans showed widespread metastatic disease involving the lung and retroperitoneal lymph nodes (Fig. 1c, Fig. 1d). She began systemic treatment with a standard bladder cancer regimen consisting of gemcitabine and cisplatin. CT scans, performed after 3 cycles (3 months) of treatment, showed progressive retroperitoneal lymphadenopathy, so she was switched to second-line paclitaxel and carboplatin. This regimen was well-tolerated and CT scans done after 3 and 6 cycles showed stable disease, but scans after 9 cycles showed progression in both the lung and the peritoneum. She then received capecitabine and an oral antiangiogenic agent as part of a phase 1 trial. On this regimen, she had initial disease stabilization, but after 6 cycles had significant clinical and radiological progression with the appearance of large adnexal masses, malignant ascites and lesions in the urachal remnant and omentum. She also required bilateral nephrostomy tubes due to ureteric compression from her disease. She came off the trial and started on a single agent, irinotecan, intravenously every 3 weeks. Despite initial symptomatic benefit, further radiologic progression was seen after 3 cycles. She was then given a brief 6-week course of oral cylophosphamide+prednisone, but the disease progressed. She then had a cycle of capecitabine+oxaliplatin (XELOX), which became available on a compassionate basis, but unfortunately she died of further disease progression.

Discussion

Urachal cancers are rare and aggressive cancers of the bladder which were originally described by Hue and Jacquin in...
1863. They account for only 0.5% of all bladder cancers, and 20% to 40% of primary bladder adenocarcinomas. To date, there have been no randomized trials and fewer than 300 cases reported in the literature. As a result, there is a paucity of information on how best to manage these cancers and specifically which chemotherapeutic agents are most effective in an atypical bladder cancer with histological and biological features similar to cancers of the bowel.

Urachal cancers arise from the urachus which is a vestigial embryonic structure located in the space of Retzius, between the transversalis fascia anteriorly and peritoneum posteriorly and between the dome of the bladder and the umbilicus. The urachus is composed of three layers: an outer muscular layer, middle connective tissue layer and an inner layer usually lined with transitional cell epithelium. Most urachal carcinomas are mucin-producing adenocarcinomas which exhibit signet ring cells and an enteric type histology more commonly seen in colon cancers. The MD Anderson Cancer Center (MDACC) criteria helps in the diagnosis of urachal cancers (Table 1). These criteria include a midline location of the tumour; a sharp demarcation between the tumour and normal surface epithelium; an enteric type histology; the absence of urothelial dysplasia, cystitis cystica or cystitis glandularis transitioning to the tumor; and the absence of a primary adenocarcinoma of another origin.

Patients with urachal cancers often present with higher stage disease at diagnosis because the disease has progressed further and grown into the bladder secondarily. When symptoms occur they commonly include irritative voiding symptoms, discharge of mucous-like material and gross hematuria. Some patients also report umbilical pain and umbilical discharge. The standard workup includes CT or MRI evaluation of the abdomen and pelvis with a chest x-ray or preferably CT chest to rule out lung metastases. Cystoscopy and an exam under anesthesia with biopsy of the suspicious area is recommended. As with other enteric malignancies, elevations in tumour markers, including carcinoembryonic antigen (CEA), CA125 and cancer antigen 19-9, have been reported and in some cases a decrease in levels may correlate with response to systemic treatment. If a diagnosis of urachal cancer cannot be made, a search for an alternate primary oncological diagnosis is recommended.
An en bloc resection of the urachal ligament and umbilicus is recommended for patients who have surgically resectable disease and either a complete or partial cystectomy ensuring negative margins. This is crucial because urachal tumours can occur anywhere along the urachus, including at the umbilicus (7%). If the urachus is transected during surgery, spillage of the tumour containing fluid into the peritoneal cavity can increase the risk of relapse. Currently, an open surgical approach is favoured due to the lack of long-term data on either laparoscopic or robotic surgeries.

Two systems have been proposed for staging urachal cancers. The first system was proposed by Sheldon and colleagues in 1984. In the Sheldon staging system, early stage urachal cancers are localized to the urachal mucosa, while late stage disease involves the local structures, such as the bladder, abdominal wall or peritoneum, and metastases to regional lymph nodes or distant sites. A more simplified system has been recently proposed by the Mayo clinic, though neither system has been validated. The median survival for locally advanced or metastatic disease is between 12 and 24 months and the 5-year cancer specific survival rate for urachal cancers is only 50%.

Unlike other cancers, there is currently no standard adjuvant or metastatic chemotherapy regimen for the treatment of urachal cancers. The choice of regimens has been largely on case reports and single institution experiences. Chemotherapy regimens used and available in Canada to treat advanced bladder cancer, including gemcitabine+cisplatin or methotrexate+vinblastine+doxorubicin+cisplatin (MVAC), have shown a few anecdotal responses in urachal cancers, but have generally yielded disappointing results. Given the enteric-type histology of urachal adenocarcinomas, chemotherapy regimens used to treat gastrointestinal malignancies may be more effective. Two case reports have described patients responding to irinotecan-based chemotherapy, a regimen commonly used to treat colorectal cancers. Two case reports using oxaliplatin-based chemotherapy have also shown benefit in urachal cancers. There is one report of a triplet combination of...
5-fluorouracil+doxorubicin+mitomycin-C showing activity in this disease." In terms of clinical trials, there was one trial of a triplet combination of ifosfamide+paclitaxel+cisplatin in advanced non-transitional cell carcinoma that has reported some activity in urachal cancers. There is also a phase II study evaluating gemcitabine+fluorouracil+leucovorin+cisplatin (GemFLP) in metastatic urachal cancer and other adenocarcinomas of the bladder, and preliminary results from this study are encouraging. With the lack of other effective options, this regimen has been adopted as the adjuvant and front-line metastatic regimen at the MDACC.7

In this case of advanced urachal cancer, taxanes and 5FU-based therapy may have slowed disease progression, similar to reports in larger case series with these agents. The response to taxanes is not surprising since taxanes have demonstrated efficacy in primary adenocarcinomas.21 Our patient responded favorably to capecitabine likely based on the enteric histology. She may have had some additional benefit from the antiangiogenic agent, but this would have to be tested in the context of a larger clinical trial. There

Table 3. Chemotherapy regimens tested in urachal cancers

<table>
<thead>
<tr>
<th>Regimen</th>
<th>N</th>
<th>Setting</th>
<th>Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-1+cisplatin ×5 courses22</td>
<td>1</td>
<td>Metastatic</td>
<td>1 complete response, disease-free at 30 months</td>
</tr>
<tr>
<td>S-1+cisplatin23</td>
<td>1</td>
<td>Metastatic</td>
<td>1 response</td>
</tr>
<tr>
<td>FOLFOX418</td>
<td>1</td>
<td>Perioperative</td>
<td>Minor response to chemotherapy, no recurrence after 1.5 years</td>
</tr>
<tr>
<td>Irinotecan24</td>
<td>1</td>
<td>Metastatic</td>
<td>Partial response (tumour resistant to cisplatin, 5-FU, doxorubicin, epirubicin, mitomycin-C)</td>
</tr>
<tr>
<td>IFL25</td>
<td>1</td>
<td>Metastatic</td>
<td>Complete response, recurrence after 6 months</td>
</tr>
<tr>
<td>Cisplatin+paclitaxel+ifosfamide26</td>
<td>6</td>
<td>Advanced</td>
<td>1 partial response, 4 with stable disease (duration of response not reported)</td>
</tr>
<tr>
<td>5-FU+doxorubicin+VP16,doxorubicin+mitomycin-C+cisplatin</td>
<td>1</td>
<td>Metastatic</td>
<td>Both survived over 10 years, chemotherapy was given in the context of multimodality treatment</td>
</tr>
<tr>
<td>Doxorubicin+mitomycin-C+ cisplatin, uracil/ftorafur27</td>
<td>1</td>
<td>Metastatic</td>
<td>2 responses</td>
</tr>
<tr>
<td>Methotrexate+5-FU+epirubicin+cisplatin16,27</td>
<td>1</td>
<td>Metastatic</td>
<td>Complete response</td>
</tr>
<tr>
<td>Ifosfamide+5-FU+VP16+cisplatin27</td>
<td>4</td>
<td>Metastatic</td>
<td>1 complete response, 2 partial response</td>
</tr>
<tr>
<td>Cisplatin+5-FU8</td>
<td>9</td>
<td>Metastatic</td>
<td>3/9 partial responses</td>
</tr>
<tr>
<td>MVAC8</td>
<td>5</td>
<td>Metastatic</td>
<td>No response</td>
</tr>
<tr>
<td>Taxol+methotrexate+cisplatin8</td>
<td>1</td>
<td>Metastatic</td>
<td>Response</td>
</tr>
<tr>
<td>Gem-FLP7 ongoing Phase II trial</td>
<td>Metastatic</td>
<td>1 complete response, multiple partial responses</td>
<td></td>
</tr>
</tbody>
</table>

S-1: oral fluoropyrimidine; FOLFOX4: oxaliplatin 85 mg/m2 (D1), leucovorin 200 mg/m2 (D1,2), fluorouracil 400 mg/m2 (D1, D2), fluorouracil 600 mg/m2 CIV over 22 hours (D1,2); IFL: irinotecan 125 mg/m2, 5FU 500mg/m2, leucovorin 20mg/m2, once weekly for 4 to 6 weeks; MVAC: methotrexate, vinblastine, adriamycin, cisplatin; Gem-FLP: gemcitabine, 5FU, leucovorin, cisplatin.
was little response to either irinotecan or oxaliplatin, but this could easily have been attributed to the fact that she was already heavily pretreated by the time these agents became available on a compassionate basis. These agents, if available earlier, may have had more benefit. This raises an important issue regarding drug access and availability for patients with rare cancers. Often, there is no phase III clinical trial evidence and biological behaviour may differ from the site of origin necessitating the use of alternate treatment strategies. As we move towards a more personalized approach in oncology, treating according to the histology or other molecular features may improve outcomes in rare cancers such as this one.

**Conclusion**

Despite limited evidence, standard chemotherapy for patients with urachal adenocarcinoma should include a taxane or a regimen commonly used to treat gastrointestinal malignancies as opposed to standard transitional cell carcinoma regimens which have not shown much efficacy. The results of the phase II trial of gemcitabine+ cisplatin+5-FU might further define a treatment standard for this disease.

Ultimately, the inclusion of urachal cancer patients in clinical trials will be critical and may also be a mechanism to overcome drug access issues. Studies exploring the use of neoadjuvant, adjuvant or perhaps even intraperitoneal chemotherapy for urachal cancers may lead to better treatment strategies and ultimately better outcomes in this disease.

**Competing interests:** None declared.

This paper has been peer-reviewed.

**References**


**Correspondence:** Dr. Srikala S. Sridhar, Medical Oncologist, Princess Margaret Hospital, Assistant Professor, Department of Medicine, University of Toronto, 5222 - 610 University Ave., Toronto, ON M5G 2M9; fax: 416-946-6546; srikala.sridhar@uhn.on.ca